The alarmins S100A8 and S100A9 are damageassociated molecular patterns, which play a pivotal role in cardiovascular diseases, inflammation, and viral infections. We aimed to investigate their role in Coxsackievirus B3 (CVB3)-induced myocarditis.
M
yocarditis is defined as an inflammatory cardiac disorder mostly caused by viral infections and is a main cause of heart failure in young adults. 1, 2 Under classical pharmacological heart failure treatment, myocarditis can progress to a dilated phenotype inflammatory dilated cardiomyopathy with an impaired prognosis, indicating the need for a further development of target-specific strategies. 3 Most information on the pathophysiology of viral myocarditis is available in Coxsackievirus B3 (CVB3)-induced experimental or human myocarditis. CVB3 infection induces cardiac damage via a direct cardiomyocyte cytopathic effect 4 and by an activation of a severe reaction of the immune system. [5] [6] [7] Accumulating evidence indicates that in addition, oxidative stress leads to an aggravation of myocardial injury [8] [9] [10] and may exacerbate inflammation. 11, 12 The alarmins S100A8 and S100A9 are calcium (Ca 2+ )-binding cytosolic proteins defined by 2 Ca 2+ -binding, so called, EF hands and are damage-associated molecular patterns. 13 They belong to the S100A family and are directly linked to the innate immune system. 13 These alarmins are abundantly expressed in neutrophils and monocytes and are released during inflammatory conditions. 13 Furthermore, they predominantly form the heterodimer S100A8/S100A9, 14 which has a proinflammatory character under certain conditions and also has physiological functions, 13 whereas S100A8 and S100A9 homodimers are proinflammatory per se. 15 S100A8 and S100A9 are involved in inflammatory cell migration 16 and induce reactive oxygen species (ROS) production. 17 They are recognized by pattern recognition receptors, 13 such as the RAGE (receptor for advanced glycation endproducts), 18 which regulates the migration of inflammatory cells 16 and oxidative stress. 19 Accumulating evidence demonstrates an involvement of S100A8 and S100A9 in cardiovascular disorders, like coronary artery disease, 20 and during viral infections, 21 making them an appealing therapeutic target. 22 Furthermore, clinical evidence highlights that high plasma levels of S100A8/S100A9 are a risk factor for future myocardial infarctions and cardiovascular death in healthy individuals 20 indicating the potential of S100A8/S100A9 as a potential biomarker. 22 We aimed to investigate the role of S100A8/S100A9 in myocarditis. Therefore, we characterized these alarmins in endomyocardial biopsies (EMBs) of patients with and without myocarditis, as well as in experimental CVB3 models, including S100A8/S100A9 knockout animals and under cell culture conditions.
MATERIALS AND METHODS
Detailed Materials and Methods are available in the Data Supplement.
Patient Characteristics
For the analysis of S100A8 and S100A9 in EMBs, the study group comprised patients with an EMB-proven cardiac infection of CVB3 (n=14), patients who eliminated cardiac CVB3 infection over time (n=5), proven by follow-up EMBs, and CVB3-negative dilated cardiomyopathy (DCM; n=10) patients without cardiac inflammation. Patients served as controls (n=10) where a cardiac cause for exercise limitation or chest complaints could be excluded after several investigations, including regular findings in their EMBs (Table I in the Data  Supplement) . Coronary artery disease was angiographically excluded in all patients. All diagnostic procedures and evaluation were obtained by using standardized protocols. 23, 24 All patients provided written consent for the procedures. The investigation conforms with the principles outlined in the Declaration of Helsinki.
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S100A9 Knockout Mice
The ubiquitous S100A9 knockout ( −/− ) mice were generated by disrupting the S100A9 gene via homologous recombination. 26 Male S100A9 −/− and wild-type (WT) mice had both the C57BL6/j background. Left ventricular (LV) S100A9 mRNA expression was undetectable in S100A9 −/− and S100A9 −/− CVB3 animals ( Figure I in the Data Supplement). These animals are also deficient of S100A8 on protein level, 26 representing a functional double −/− , as also shown in the LV ( Figure I in the Data Supplement). The experimental groups included control WT (C57BL6/j), S100A9 −/− , WT CVB3, and S100A9 −/− CVB3 (n=7 for WT and WT CVB3, n=8 for S100A9 −/− , and n=10 for S100A9 −/− CVB3). The experiments followed the guidelines of the US National Institutes of Health, "Guide for the Care and Use of
WHAT IS NEW?
• The present study demonstrates the importance of the damage-associated molecular patterns S100A8 and S100A9 in the pathogenesis of Coxsackievirus B3 (CVB3)-induced myocarditis.
• CVB3 infection elevates cardiac S100A8 and S100A9 expression in humans and mice.
• A cardiac decrease of S100A8 and S100A9 expression in CVB3-positive patients is associated with an improved clinical course.
• Loss of S100A9 and S100A8 rescues CVB3-infected myocarditis mice from cardiac inflammation and oxidative stress.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Currently, no target-specific treatment options exist for myocarditis, an inflammatory cardiac disorder.
• The present finding that S100A8 and S100A9 are important mediators in the pathogenesis of CVB3-induced myocarditis and the existence of anti-S100A9-specific compounds open a new potential avenue for treatment of CVB3 myocarditis.
Laboratory Animals," published by the US National Institutes of Health (publication No. 85-23 revised, 1985) and were approved by the local ethics committee (Landesamt für Gesundheit und Soziales, Tierschutz, Berlin).
Cell Culture Experiments
The murine cardiomyocyte-like cell line HL-1 was cultured in full Claycomb medium, consisting of Claycomb medium (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) supplemented with 10% fetal bovine serum (FBS; Biochrom, Berlin, Germany), 1% penicillin/streptomycin (Biochrom), 0.1 mmol/L norepinephrine (Sigma-Aldrich Chemie GmbH), and 2 mmol/L L-glutamine (Biochrom). RAW macrophages were cultured in RPMI 1640 full medium, consisting of RPMI 1640 medium (Gibco, Karlsruhe, Germany) supplemented with 10% FBS and 1% penicillin/streptomycin.
S100A8 siRNA Transfection and CVB3 Infection
In preliminary experiments, we found that RAW macrophages do not express S100A9. Consequently, we only knocked down S100A8 in RAW cells. RAW cells were transfected with 15 nmol/L of S100A8 and scrambled siRNA (Life Technologies GmbH, Darmstadt, Germany) via lipofectamine RNAiMAX (Life Technologies GmbH). The S100A8 knockdown efficacy in RAW macrophages can be retrieved in Figure II in the Data Supplement. CVB3 infection at a multiplicity of infection of 2 occurred 24 hours after transfection. One hour postinfection, RAW cells were cultured for further 24 hours and subsequently collected for RNA isolation. All described experiments consist of 5 to 6 samples per group and condition.
Stimulation With S100A8 and S100A9 Proteins and CVB3 Infection HL-1 and RAW cells were infected with CVB3 at a multiplicity of infection of 2 for 1 hour. Subsequently, cells were stimulated with S100A8 or S100A9 at a final concentration of 5 μg/mL. Twenty-four hours later, HL-1 and RAW cells were collected for RNA isolation. Additionally, HL-1 cells, which were infected at a multiplicity of infection of 4, were used for flow cytometry 4 hours post-infection. All described experiments consist of 5 to 6 samples per group, cell line, and condition, with an exception for the determination of CVB3 copy number and IFN-β (interferon-β) in HL-1 cells. There the sample size varied from 4 to 6 per group and condition.
RNA Isolation, cDNA Synthesis, and Gene Expression Analysis
Total RNA isolation was performed, followed by cDNA synthesis with the High Capacity Kit (Life Technologies GmbH).
To assess the relative mRNA expression, real-time polymerase chain reaction was performed using gene expression assays from Life Technologies (Table II in the Data Supplement).
Western Blot
Murine LV homogenates were used for S100A8 and S100A9 protein detection by using specific antibodies followed by a near infrared fluorescent dye-conjugated secondary antibody (primary antibody: S100A8 or S100A9 
Myeloperoxidase ELISA
To detect cardiac myeloperoxidase activity, 100 µL of LV homogenates, containing 2.5 µg protein, were analyzed by using the ELISA kit of Cloud-Clone Corp, (Houston) according to the manufacturer's protocol.
Intracellular ROS Flow Cytometry
Four hours after infection and stimulation with S100A8 and S100A9, cells were detached and pelleted. Finally, cell pellets were incubated with 5 µM chloromethyl-2',7'-Dichlorodihydrofluorescein-diacetate (CM-H 2 DCF-DA) per sample (Invitrogen, Heidelberg, Germany) and analyzed as described previously. 27 Data are expressed as ROS + cells (percentage gated cells).
Immunohistological Investigations of Macrophages and Collagen Expression
The obtained tissue samples of the LVs were embedded in Tissue-Tek OCT compound (Sakura, Zoeterwoude, NL). Immunohistochemistry was performed with specific antibodies directed against CD68 (rabbit anti-CD68; Bioss, Freiburg, Germany), collagen I (rabbit anti-Col I; Chemicon), and collagen III (rabbit anti-Col III; Calbiochem). In summary, quantification was performed by digital image analyses using a ×200 magnification.
Immunohistological Investigations of S100A8 and S100A9 in Human Biopsies
EMBs were paraffin embedded and were deparaffinized before staining by using Xylol followed by decreasing ethanol series. Immunohistochemistry was performed with specific human S100A8 or S100A9 antibodies (S100A8 or S100A9 anti-human rabbit; Thomas Vogl, Münster, Germany). Subsequently, a peroxidase-labeled polymer conjugated to goat anti-rabbit immunoglobulins was used and was visualized by the Envision peroxidase technique (EnVision goat antirabbit; Dako, Hamburg, Germany).
Immunofluorescence Investigations of S100A8 and S100A9 Expression
Colocalization of S100A8 and S100A9 was determined on successive Tissue-Tek OCT-embedded human biopsy and LV tissue samples, by using a specific human or mouse S100A8 or S100A9 antibody, respectively (S100A8 or S100A9 antihuman or anti-mouse rabbit). For the identification of specific S100A8 or S100A9 expressing cells, a double staining was performed (for mouse S100A8 and S100A9 staining as mentioned above; primary antibodies: CD68 anti-mouse rat 
Statistical Analysis
A 2-tailed t test for normal distributed data comparisons or a Mann-Whitney U test for non-normal distributed data comparisons was used for the comparison of LV S100A8 and S100A9 protein expression in WT versus WTCVB3 mice, in S100A9 −/− versus S100A9 −/− CVB3 mice for S100A8 mRNA levels, and WT versus WTCVB3 mice for S100A8 protein levels, and CVB3 copy number in WTCVB3 versus S100A9 −/− CVB3 mice, for the evaluation of S100A8 knockdown efficacy in S100A8 siRNA-transfected RAW cells and for the comparison of hemodynamic parameters in CVB3-infected S100A9 −/− mice with and without cotreatment with S100A8. Normal distribution was visually checked by using box plots. 28 For the normal distributed pairwise comparisons of EMB S100A8 and S100A9 mRNA expression in patients with CVB3 who eliminated the virus over time, a 2-tailed paired t test was used. The Kruskal-Wallis analysis of variance was used for the comparison of clinical data of controls and patients with DCM and patients with CVB3-positive myocarditis. An ANOVA was used for normal distributed data comparison of in vitro knockdown and stimulation experiments, in vivo experiments in WT, S100A9 −/− , WTCVB3, and S100A9 −/− CVB3 mice, and S100A8 and S100A9 EMBs measurements in control, DCM, and patients with CVB3-positive myocarditis. In case of unequal distribution and heterogeneous SDs, the Welch ANOVA test was performed. Overall, a Bonferroni post hoc test was used. A P<0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism 
RESULTS
Impact of CVB3 Infection on S100A8 and S100A9 Expression
Analysis of EMB S100A8 and S100A9 mRNA levels showed a 13-fold (P=0.012) and 5.1-fold (P=0.038) increase in CVB3-positive patients versus controls, respectively, whereas the alarmin levels were not changed in patients with DCM versus controls (Figure 1A and 1B; patient characteristics in Table I in the Data Supplement). Further evaluation of S100A8 and S100A9 mRNA levels in former CVB3-positive patients, who eliminated the CVB3 virus over time, as proven by follow-up EMBs (mean after 8.5 months), showed 5.2-fold (P=0.039) and 4.5-fold (P=0.030) lower S100A8 and S100A9 mRNA levels compared with the results of the initial investigation of these patients ( Figure 1C and 1D). The drop in S100A8 and S100A9 expression levels was associated with an improvement in LVEF (39±4.1% to 53±6.0%; P=0.056). This drop in S100A8 and S100A9 expression was also detectable on protein level ( Figure III in the Data Supplement). Immunofluorescence further provided evidence for cardiac S100A8 and S100A9 coexpression on protein level ( Figure IV in the Data Supplement). In C57BL6/j mice, CVB3 infection induced a 41-fold (P=0.00 060) and a 19-fold (P=0.0090) enhancement of LV S100A8 and S100A9 protein expression compared with uninfected WT mice, respectively ( Figure 1E and 1F) . Representative immunofluorescence pictures of CVB3-infected mice LVs showed an enhanced S100A8 and S100A9 expression compared with WT mice, and the congruency of these 2 alarmins indicates a coexpression ( Figure 1G and 1H) . Furthermore, double stainings revealed S100A8 and S100A9 expression in macrophages, monocytes, and neutrophils under CVB3 conditions (Figure V in the Data Supplement).
Impact of S100A9 −/− on LV Infiltration of Neutrophils and Monocytes in CVB3-Infected Mice
As shown in Figure VIA in the Data Supplement, LV mRNA expression of the chemokine MIP-2 (macrophage inflammatory protein-2) was 2.0-fold (P=0.037) lower in S100A9 −/− CVB3 versus WT CVB3 mice, which was accompanied by 2.1-fold (P=0.059), 2.2-fold (P=0.053), and 1.3-fold (P=0.048) lesser LV mRNA levels of the neutrophil marker, Ly6g, of the monocyte marker, Ly6c, and of CD68-positive cells in the LV, respectively (Figure 2A through 2C) .
To further understand the impact of S100A8 and S100A9 on MIP-2, we performed in vitro stimulation and knockdown experiments in RAW macrophages. S100A8 or S100A9 supplementation to CVB3-infected RAW cells increased MIP-2 mRNA levels in a 8.4-fold (P<0.00 010) and 4.6-fold (P<0.00 010) manner versus the CVB3 unstimulated group, respectively (Figure VIB in the Data Supplement). In accordance with the in vivo data, S100A8 siRNA CVB3 RAW cells displayed a moderate but significant 1. 
Impact of S100A9 −/− on LV Oxidative Stress in CVB3-Infected Mice
Because neutrophils and macrophages are important sources of oxidative stress, 29 we next evaluated the impact of S100A9 −/− on oxidative parameters in CVB3-induced myocarditis. WT CVB3 mice showed a 2.0-fold (P=0.0030) enhancement of myeloperoxidase activity compared with WT mice ( Figure 3A) . In contrast, S100A9
−/− CVB3 mice displayed a 3.0-fold (P<0.00 010)
lower myeloperoxidase activity versus WT CVB3 mice ( Figure 3A ). In parallel, mRNA expression of NADPH oxidase (Nox) 1 was 3.3-fold (P=0.016) lower in S100A9 −/− CVB3 animals compared with WT CVB3 mice, whereas no significant changes in Nox2 and Nox4 mRNA levels were found in the infected knockout versus the respective WT CVB3 mice ( Figure 3B through 3D) . Also, supplementation of S100A8 and S100A9 to CVB3- A, S100A8 and, B, S100A9 mRNA expression in endomyocardial biopsies (EMBs) of CVB3-negative controls and patients with dilated cardiomyopathy (DCM) and CVB3-positive patients. C, S100A8 and, D, S100A9 mRNA expression in EMBs of CVB3-positive patients who eliminated the virus over time depicting S100A8 and S100A9 mRNA expression (n=5). All data are reported as the mean±SEM with n=10 for controls and for CVB3-negative patients with DCM and n=14 for CVB3-positive myocarditis (MC) patients. Left ventricular (LV) protein expression of (E) S100A8 and (F) S100A9 in wild-type (WT) CVB3 mice compared with respective noninfected mice. All data are reported as the mean±SEM with n=7 for WT and n=7 for CVB3 mice. Representative pictures of immunofluorescence staining for (G) S100A8 (pseudo colored in green) and (H) S100A9 (red colored) in LVs of CVB3-infected animals vs controls. The nonparametric Mann-Whitney U test for (E) S100A8 and a parametric t test for data comparison for (F) S100A9 were performed. For the whole graph panel with *P<0.05 and **P<0.005.
infected HL-1 cells further increased each of the CVB3-induced ROS levels by 1.3-fold (P=0.032 for S100A8 and P=0.051 for S100A9) compared with unstimulated CVB3-infected cells ( Figure 3E ).
Impact of S100A9 −/− on LV Fibrosis in CVB3-Infected Mice
As shown in Figure VIIA and VIIB in the Data Supplement, S100A9
−/− CVB3 mice did not show any differences in Col1a1 or in Col3a1 mRNA expression versus WT CVB3 mice, which was reflected in an unaltered collagen I/III protein ratio ( Figure VII in the Data Supplement). Analysis of the profibrotic factor TGF-β (transforming growth factor-β), which is responsible for the transformation of fibroblasts into myofibroblasts, 
Impact of S100A9 −/− on LV CVB3 Copy Number in CVB3-Infected Mice
The absence of S100A9 was associated with a 2.3-fold (P=0.0496) reduction of CVB3 copy number and a 2.0-fold (P=0.015) increase of IFN-β mRNA expression when comparing S100A9 −/− CVB3 mice with WT CVB3 (Figure 4A and 4B) . Complementary to the in vivo results, supplementation of S100A8 or S100A9 to CVB3-infected HL-1 cells resulted each in a 2.0-fold (P<0.00 010) increase of CVB3 copy number and led to 4.4-fold (P<0.00 010) and 7.3-fold (P<0.00 010) decreased mRNA levels of the anti-viral cytokine IFN-β, respectively, compared with unstimulated CVB3 HL-1 cells (Figure 4C  and 4D ). Given the importance of the CAR (Coxsackievirus and adenovirus receptor) for the infectivity of cells by CVB3, 31 we next evaluated whether the lower CVB3 copy number in S100A9 −/− CVB3 versus CVB3 mice could be because of differences in CAR expression. S100A9 −/− CVB3 mice exhibited 1. 
Impact of S100A9 −/− on RAGE Expression in LVs of CVB3-Infected Mice
Because S100A8 and S100A9 alarmins are known to signal among others via RAGE, 18 we next evaluated the impact of S100A9 −/− on LV RAGE signaling. LV mRNA expression of RAGE and its adaptor Dia-1 (diapha- , and WT CVB3 and n=10 in S100A9 −/− CVB3 mice. For Nox1, Nox2, and Nox4 with n=5 in WT, n=7 in S100A9 −/− , n=6 in WT CVB3, and n=9 in S100A9 −/− CVB3 mice, with the exception for Nox1 with n=4 in WT animals. For stimulation experiment with n=6 per group, with the exception for S100A8 CVB3 with n=5. For the whole graph panel with *P<0.05, **P<0.005, and ***P<0.0005.
nous-1)
32 decreased by 2.2-fold (P=0.0010) and 3.0-fold (P=0.015) in S100A9 −/− CVB3 versus WT CVB3 mice ( Figure 5A and 5C ), respectively. Myeloid differentiation primary response 88, which is also an adaptor of RAGE, 18 showed no differences between S100A9 −/− CVB3 and WT CVB3 animals ( Figure 5B ).
Impact of S100A9 −/− on LV Hemodynamic Function in CVB3-Infected Mice
Global heart function was improved in S100A9 −/− CVB3 mice compared with WT CVB3 mice, as shown by a 69% (P<0.00 010), 251% (P=0.017), and 343% (P=0.028) enhancement of EF, cardiac output, and stroke work function, respectively (Table 1) . Moreover, S100A9 −/− CVB3 mice exhibited an improved systolic and diastolic function compared with WT CVB3 mice as indicated by a 34% (P=0.034), 96% (P=0.027), and 150% (P=0.009) improved maximum LV pressure, maximal LV pressure rise rate, and maximum LV pressure drop rate, respectively ( Table 1) .
Impact of S100A8 Supplementation on LV CVB3 Copy Number, Inflammation, and LV Function in S100A9 −/− CVB3-Infected Mice
Finally, to confirm the deteriorating effect of S100A8 and S100A9, we supplemented S100A8-the smaller subunit of the heterodimer S100A8/S100A9 13 -to S100A9 −/− CVB3 mice. S100A8 supplementation resulted in a higher CVB3 copy number (S100A9 −/− CVB3 mice and for IFN-β with n=7 in WT CVB3 and n=8 in S100A9 −/− CVB3 mice. C, CVB3 copy number and (D) IFN-β mRNA levels in CVB3-infected, S100A8-or S100A9-stimulated CVB3-infected HL-1 cells vs their respective controls, 24 h post-infection and stimulation. Bar graphs represent the mean±SEM with n=6 in CVB3, n=5 in S100A8 CVB3, and n=4 in S100A9 CVB3 HL-1 cells. (Table 2) . Moreover, S100A9
−/− CVB3+S100A8 mice exhibited a decreased systolic and diastolic function compared with S100A9 −/− CVB3 mice as indicated by a 49% (P=0.0061), 60% (P=0.0061), and 66% (P=0.034) impaired maximum LV pressure, maximal LV pressure rise rate, and maximum LV pressure , n=5 in WT CVB3, and n=10 in S100A9 −/− CVB3 mice, and for Dia-1 with n=5 in WT, n=6 in S100A9 −/− and WT CVB3, and n=9 in S100A9 −/− CVB3 mice. For the whole graph panel with *P<0.05, **P<0.005, and ***P<0.0005. drop rate, versus S100A9 −/− CVB3 mice, respectively (Table 2) . Overall, the supplementation led to a restoration of the WT CVB3 phenotype, which is clearly demonstrated by the comparison of Tables 1 and 2 .
DISCUSSION
In the present study, we demonstrated the pathophysiological role of the damage-associated molecular patterns S100A8 and S100A9 in cardiac CVB3-induced myocarditis. This follows from the observations that S100A9 −/− CVB3 mice showed an improved LV function, lower LV MIP-2 expression, associated with less cardiac infiltrates of neutrophils and monocytes, a reduced LV oxidative stress, lower CAR mRNA expression and CVB3 copy number, and alterations in RAGE and Dia-1 expression compared with WT CVB3 mice. Intraperitoneal application of S100A8 in S100A9 −/− CVB3 mice induced the CVB3 copy number and cardiac inflammation versus S100A9 −/− CVB3 mice and resulted in an impaired cardiac function resembling the WT phenotype again. In line with our in vivo findings, we confirmed the deteriorating effects of S100A8 and S100A9 in vitro, where stimulation with S100A8 or S100A9 of CVB3-infected cells, such as HL-1 cells or RAW macrophages, resulted in an enhanced MIP-2 expression, a higher oxidative stress, and higher CVB3 copy number, whereas S100A8 −/− resulted in lower MIP-2 expression. Finally, the relevance of S100A8 and S100A9 follows from our observations that CVB3-positive patients express more S100A8 and S100A9 versus CVB3-negative patients and that a cardiac decrease of S100A8 and S100A9 expression is associated with an improved clinical course, as displayed in CVB3-positive patients, who eliminated the CVB3 virus over time. Interestingly, in contrast to our data, Otsuka et al 33 demonstrated that administration of S100A8/S100A9 in an experimental setting of autoimmune myocarditis was protective. This observation emphasizes that the fate of a certain molecule, be it pathogenic or protective, depends on the disease. As described above, we demonstrated the negative role of S100A8/S100A9 in CVB3-induced myocarditis, including in vivo, in vitro, and patient data. Furthermore, the fact that patients with viral infections have elevated S100A8 and S100A9 levels and the observation of Ryckman et al, 34 who showed that these both alarmins induce HIV-1 transcription activity and virus replication in CD4+ T-lymphocytes, support the pathogenic role of S100A8 and S100A9 under viral conditions. CVB3 infection induces cardiac damage via a direct cardiomyocyte cytotoxic effect, 4 an increased inflammatory cell migration, 35 and oxidative stress. 36 Accumulating evidence indicates that in addition, oxidative stress leads to an aggravation of myocardial injury [8] [9] [10] and may exacerbate inflammation. 11, 12 Overall, immunofluorescence double-stainings revealed macrophages, monocytes, and neutrophils to express S100A8 and S100A9 under CVB3 conditions versus controls, which has already been described for other inflammatory conditions. 37 This fact in turn may account for the diminished presence of inflammatory cells in S100A9 −/− CVB3 mice compared with infected mice, because S100A8 and S100A9 are responsible for leukocyte migration. 37 The reduced infiltration of monocytes and neutrophils in S100A9 −/− CVB3 compared with WT can also be explained via the downregulated expression of the chemokine MIP-2, known to play a crucial role in the inflammatory course of CVB3-induced myocarditis, 35 found in S100A9 −/− CVB3 compared with WT CVB3 mice. This was further corroborated by Vogl et al, 38 who demonstrated a decreased MIP-2 expression after lipopolysaccharide stimulation of bone marrow-derived cells originated from S100A9
−/− mice compared with WT mice. The impact of S100A8 and S100A9 on MIP-2 expression is supported by our in vitro stimulation experiments in RAW macrophages. However, our S100A8 knockdown examinations showed only a moderate effect on MIP- 2 in RAW macrophages, in contrast to the more pronounced MIP-2 downregulation observed in S100A9 −/− CVB3 versus WT CVB3 mice. This can be explained by the fact that in the heart, cells other than macrophages are also present, which express MIP-2, including mast cells, endothelial cells, and cardiomyocytes. 39 Conform to the reduced cell infiltration of neutrophils and monocytes/macrophages, S100A9 −/− CVB3 mice displayed a lower cardiac activity of myeloperoxidase, which is particularly expressed in neutrophils and macrophages, 29 versus WT CVB3 mice. Furthermore, a reduced LV mRNA expression of the NADPH oxidase member, Nox 1 was observed, 40 which is together with Nox2 and Nox4 predominately expressed in the cardiovascular system. 41 We found no significant expression changes of cardiac Nox2 and Nox4 between the 2 infected groups. Based on these data and the fact that S100A8 and S100A9 are important regulators of NADPH oxidases 17 we suggest that under CVB3 conditions, S100A8 and S100A9 seem to predominately influence the Nox 1 isoform.
In vitro, we showed that S100A8 or S100A9 stimulation of CVB3-infected HL-1 cells resulted in elevated ROS production compared with unstimulated CVB3 cells. Overall, our findings are consistent with other studies demonstrating a reduced myeloperoxidase activity in S100A9 −/− atherosclerosis mice 42 and diminished ROS production in S100A9 −/− mice. 17 In harmony with the decreased cardiac oxidative stress, which is of relevance for the replication of CVB3, 10 a complete loss of S100A9 and S100A8 proteins in vivo led to a decreased CVB3 copy number in infected animals. This might further be explained by the lower cardiac expression of CAR, relevant for CVB3 uptake, 31 and by enhanced levels of antiviral IFN-β compared with WT CVB3 mice. In addition, intraperitoneal application of S100A8 to S100A9 −/− CVB3 mice induced the CVB3 copy number versus S100A9 −/− CVB3 mice, further confirming the deteriorating character of this alarmin. In vitro, S100A8 or S100A9 supplementation to CVB3-infected HL-1 cells resulted both in declined IFN-β levels, paralleled by increased CVB3 copy number compared with the respective unstimulated CVB3-infected cells, which is, with respect to S100A8, in accordance to our in vivo data, where S100A8 supplementation led to an enhanced CVB3 copy number in S100A9 −/− CVB3 mice. Our findings are conformed with the observation that S100A8 and S100A9 are elevated in patients with viral infection. 21 With respect to myocarditis, we were able to show higher cardiac tissue expression of S100A8 and S100A9 in human CVB3-induced myocarditis versus controls, which decreased after virus elimination and healing. Interestingly, one of the patients, who eliminated the CVB3 virus, showed an unchanged cardiac S100A8 and S100A9 expression between time point 1 and time point 2. This observation might be explained by the fact that this particular patient had a lower CVB3 viral load at time point 1 in comparison with the other CVB3-positive patients, suggesting that the change in S100A8 and S100A9 expression between time point 1 and time point 2 was not visible because of the already low initial expression levels. This observation further suggests that the induction in cardiac S100A8 and S100A9 mRNA expression may depend on CVB3. S100A8, S100A9, and S100A8/S100A9 are ligands of among others RAGE. 18 Besides the intracellular adaptor myeloid differentiation primary response 88, 18 RAGE also initiates signaling pathways via a newly discovered intracellular binding partner Dia-1. 32 In experimental cardiac inflammation and injury, S100A8/S100A9 has been shown to enhance inflammatory cell migration via RAGE, 16 which in general involves the RAGE/Dia-1 axis. 43 Also ROS, which are among others induced via S100A8 and S100A9, 17 are regulated by RAGE in cardiovascular diseases and involve the Dia-1 adaptor. 19 Our investigations demonstrated that S100A9 −/− CVB3 mice exhibited reduced cardiac RAGE and Dia-1 mRNA levels, whereby myeloid differentiation primary response 88 was unaltered compared with CVB3 mice. Based on these data, we suggest that the downregulated RAGE and Dia-1 expression could account for the diminished cardiac immune cell infiltration and oxidative stress in S100A9 −/− CVB3 compared with WT CVB3 mice. Further investigations are required confirming this link of S100A8 and S100A9 and the RAGE/Dia-1 pathway.
As a consequence of the above-discussed findings, S100A9 −/− CVB3 mice showed a significant improvement in cardiac function, which could be abolished by exogenous S100A8 application resulting in the primary CVB3 WT phenotype, which is a proof-of-concept for the specific involvement of the delirious effects of this alarmin in myocarditis. Interestingly, an improvement in matrix regulation could not be observed in S100A9 −/− CVB3 compared with WT CVB3 mice, suggesting that mechanisms independent of S100A8 and S100A9 are more prominent in collagen regulation under these conditions. Because it is known that S100A8 and S100A9 can exert also direct negative inotropic and lusitropic effects, 44 we cannot exclude that to some extent, the inhibition of these alarmins contributed directly to the preserved EF in myocarditis mice.
In summary, CVB3 infection results in an elevation of the damage-associated molecular patterns S100A8 and S100A9, which induce a signaling cascade involving RAGE/Dia-1 alterations, resulting in an increased cardiac inflammatory cell infiltration and oxidative stress. The latter is considered to lead to myocardial injury in patients with myocarditis [8] [9] [10] and may exacerbate inflammation. 11, 12 High ROS production in myocarditis 11 in turn may boost the inflammatory disorder. Loss of S100A8 and S100A9 abrogates these pathways as shown in our in vivo study. We conclude that S100A8 and S100A9 are important mediators in the pathogenesis of (CVB3)-induced myocarditis. Our data and the clinical evidence demonstrating the relevance of S100A8 and S100A9 in other cardiovascular disorders 20, 22 together with the existence of specific anti-S100A9 compounds 45 indicate that these alarmins may represent a new potential avenue for the treatment of (CVB3)-induced myocarditis and other cardiovascular disorders.
